The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Open accessAbstract
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, treated with endocrine therapies. However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance. Despite the magnitude of this clinical challenge, the mechanisms underlying the development of resistance remain largely unknown. In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approximately 20% of patients with metastatic ER-positive disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors. These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumour growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease. In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumours harbouring these mutations and the number of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance. Preclinical and clinical development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes. We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Haagenson, C. (1971) · Cited by 1,773
Vogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationActivating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Advances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
Estrogen receptor interaction with estrogen response elements
Klinge, C. M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.2905 · Cited by 1,081
Detection of ultra-rare mutations by next-generation sequencing
Schmitt, M. W., Kennedy, S. R., Salk, J. J., Fox, E. J., Hiatt, J. B., & Loeb, L. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208715109 · Cited by 1,047
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Self-citationDi Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
Huggett, J. F., Cowen, S., & Foy, C. A. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.221366 · Cited by 444
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Self-citationEstrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2006 · Cited by 375
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Nuclear Receptor Minireview Series
Olefsky, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100047200 · Cited by 308
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Self-citationZhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 291
Masson, R., Lefebvre, O., Noël, A., Fahime, M. E., Chenard, M.-P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J.-M., et al. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.6.1535 · Cited by 291
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 278
Estrogen receptors and human disease: an update
Burns, K. A., & Korach, K. S. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0868-5 · Cited by 275
Roodi, N., Bailey, L. R., Kao, W.-Y., Verrier, C. S., Yee, C. J., Dupont, W. D., & Parl, F. F. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.6.446 · Cited by 266
New Strategies in Estrogen Receptor–Positive Breast Cancer
Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230
The molecular profile of luminal B breast cancer
Creighton, C. (2012) · Biologics: Targets and Therapy · doi:10.2147/btt.s29923 · Cited by 212
Carlson, K. E., Choi, I., Gee, A., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (1997) · Biochemistry · doi:10.1021/bi971746l · Cited by 201
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
Karnik, P. S., Kulkarni, S., Liu, X.-P., Budd, G. T., & Bukowski, R. M. (1994) · PubMed · Cited by 192
Use of SERMs for treatment in postmenopausal women
Pinkerton, J. V., & Thomas, S. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.12.011 · Cited by 179
Veeraraghavan, J., Tan, Y., Cao, X.-X., Kim, J. A., Wang, X., Chamness, G. C., Maiti, S. N., Cooper, L. J. N., Edwards, D. P., Contreras, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5577 · Cited by 176
Self-citationPotential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Peng, J., Sengupta, S., & Jordan, V. C. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788451833 · Cited by 171
Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
Wang, Y., Lonard, D. M., Yu, Y., Chow, D.-C., Palzkill, T. G., Wang, J., Qi, R., Matzuk, A. J., Song, X., Madoux, F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2939 · Cited by 168
Estrogen receptors in breast carcinogenesis and endocrine therapy
Huang, B., Warner, M., & Gustafsson, J.-Å. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.11.015 · Cited by 166
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L. D., Arpino, G., Rimawi, M. F., & Osborne, C. K. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0108-2 · Cited by 165
Self-citationLupien, M., Meyer, C. A., Bailey, S. T., Eeckhoute, J., Cook, J., Westerling, T., Zhang, X., Carroll, J. S., Rhodes, D. R., Liu, X. S., et al. (2010) · Genes & Development · doi:10.1101/gad.1944810 · Cited by 165
Self-citationNFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Nettles, K. W., Bruning, J. B., Gil, G., Nowak, J., Sharma, S. K., Hahm, J. B., Kulp, K., Hochberg, R. B., Zhou, H., Katzenellenbogen, J. A., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.76 · Cited by 159
Dwyer, M. A., Joseph, J. D., Wade, H. E., Eaton, M. L., Kunder, R. S., Kazmin, D. A., Chang, C., & McDonnell, D. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0226 · Cited by 148
Skapek, S. X., Anderson, J. R., Hill, D. A., Henry, D. W., Spunt, S. L., Meyer, W., Kao, S. C.-S., Hoffer, F. A., Grier, H. E., Hawkins, D. S., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24457 · Cited by 133
Pure oestrogen antagonists for the treatment of advanced breast cancer
Howell, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00846 · Cited by 133
Acquired resistance to drugs targeting receptor tyrosine kinases
Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 129
Gattelli, A., Nalvarte, I., Boulay, A., Roloff, T. C., Schreiber, M. J., Carragher, N. O., Macleod, K., Schlederer, M., Lienhard, S., Kenner, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302625 · Cited by 97
Gundry, M. C., & Vijg, J. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.10.001 · Cited by 95
Hoefnagel, L. D. C., Moelans, C. B., Meijer, S. L., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., et al. (2012) · Cancer · doi:10.1002/cncr.27518 · Cited by 93
Huw, L.-Y., O'Brien, C. L., Pandita, A., Mohan, S., Spoerke, J. M., Lu, S., Wang, Y., Hampton, G. M., Wilson, T. R., & Lackner, M. R. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.46 · Cited by 91
Lazennec, G., Ediger, T. R., Petz, L. N., Nardulli, A. M., & Katzenellenbogen, B. S. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.9.9983 · Cited by 90
Mutant ras epitopes as targets for cancer vaccines.
Abrams, S. I., Hand, P. H., Tsang, K.-Y., & Schlom, J. (1996) · PubMed · Cited by 86
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
Fuqua, S. A. W., Gu, G., & Rechoum, Y. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2847-4 · Cited by 85
Fowler, A. M., Solodin, N. M., Preisler‐Mashek, M. T., Zhang, P., Lee, A. V., & Alarid, E. T. (2004) · The FASEB Journal · doi:10.1096/fj.03-0038com · Cited by 85
ESR1 gene amplification in breast cancer: a common phenomenon?
Reis-Filho, J. S., Drury, S., Lambros, M. B. K., Marchiò, C., Johnson, N., Natrajan, R., Salter, J., Levey, P. M., Fletcher, O., Peto, J., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-809b · Cited by 85
Yu, H. A., Riely, G. J., & Lovly, C. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2437 · Cited by 82
Drury, S., DETRE, S. I., Leary, A. F., Salter, J., Reis-Filho, J. S., Barbashina, V., Marchiò, C., López‐Knowles, E., Ghazoui, Z. F., Habben, K., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0046 · Cited by 79
Tomita, S., Zhang, Z., Nakano, M., Ibusuki, M., Kawazoe, T., Yamamoto, Y., & Iwase, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01145.x · Cited by 78
Breast cancer intratumor genetic heterogeneity: causes and implications
Ng, C. K. Y., Pemberton, H. N., & Reis-Filho, J. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.85 · Cited by 77
Rahma, O. E., Hamilton, J. M., Wojtowicz, M. E., Dakheel, O., Bernstein, S. A., Liewehr, D. J., Steinberg, S. M., & Khleif, S. N. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-55 · Cited by 74
Progress in endocrine approaches to the treatment and prevention of breast cancer
Obiorah, I. E., & Jordan, V. C. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.09.006 · Cited by 72
Barone, I., Cui, Y., Herynk, M. H., Corona‐Rodriguez, A., Giordano, C., Selever, J., Beyer, A. R., Andò, S., & Fuqua, S. A. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4194 · Cited by 71
Barone, I., Iacopetta, D., Covington, K. R., Cui, Y., Tsimelzon, A. I., Beyer, A. R., Andò, S., & Fuqua, S. A. W. (2010) · Oncogene · doi:10.1038/onc.2009.520 · Cited by 70
Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors
Dodwell, D. J., Wardley, A. M., & Johnston, S. R. D. (2006) · The Breast · doi:10.1016/j.breast.2006.01.007 · Cited by 69
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast
Piscuoglio, S., Ng, C. K. Y., Martelotto, L. G., Eberle, C. A., Cowell, C. F., Natrajan, R., Bidard, F., Mattos‐Arruda, L. D., Wilkerson, P. M., Mariani, O., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.011 · Cited by 63
Giordano, C., Cui, Y., Barone, I., Andò, S., Mancini, M. A., Berno, V., & Fuqua, S. A. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0334-0 · Cited by 58
Conway, K., Parrish, E., Edmiston, S. N., Tolbert, D., Tse, C., Geradts, J., Livasy, C., Singh, H. K., Newman, B. M., & Millikan, R. C. (2005) · Breast Cancer Research · doi:10.1186/bcr1315 · Cited by 57
Sex Hormone Receptor Repertoire in Breast Cancer
Higa, G. M., & Fell, R. G. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/284036 · Cited by 57
Improving T cell responses to modified peptides in tumor vaccines
Buhrman, J. D., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8348-9 · Cited by 57
Association between the Estrogen Receptor α A908G Mutation and Outcomes in Invasive Breast Cancer
Herynk, M. H., Parra, I., Cui, Y., Beyer, A. R., Wu, M.-F., Hilsenbeck, S. G., & Fuqua, S. A. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2608 · Cited by 54
Ooi, A., Inokuchi, M., Harada, S., Inazawa, J., Tajiri, R., Kitamura, S., Ikeda, H., Kawashima, H., & Dobashi, Y. (2011) · The Journal of Pathology · doi:10.1002/path.3974 · Cited by 52
Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 42
Spears, M., & Bartlett, J. M. S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902911509 · Cited by 36
Glück, S. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.008 · Cited by 33
The renaissance of endocrine therapy in breast cancer
Williams, N. O., & Harris, L. N. (2013) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000039 · Cited by 26
Absence of ESR1 amplification in a series of breast cancers
Adélaı̈de, J., Finetti, P., Charafe‐Jauffret, E., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23786 · Cited by 23
Elusive Extranuclear Estrogen Receptors in Breast Cancer
Levin, E. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2547 · Cited by 18
No Hypersensitive Estrogen Receptor-α Mutation (K303R) in Japanese Breast Carcinomas
Tokunaga, E., Kimura, Y., & Maehara, Y. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000019963.67754.93 · Cited by 16
Breast Cancer Adjuvant Endocrine Therapy
Cigler, T., & Goss, P. E. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318074d363 · Cited by 16
Johnston, S. R. D., & Yeo, B. J. (2014) · Current Oncology Reports · doi:10.1007/s11912-013-0358-9 · Cited by 13
ESR1 amplification in breast cancer: controversy resolved?
Albertson, D. G. (2012) · The Journal of Pathology · doi:10.1002/path.3999 · Cited by 8
Cited by
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Metadata
- Authors
- Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-06-30
- Volume
- 12
- Issue
- 10
- Pages
- 573-583
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W779403461
- Cited by
- 704
- References
- 98
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.